Opendata, web and dolomites

BiomStrip SIGNED

Over-The-Counter Test Strip for Early-Stage Cancer Screening

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 BiomStrip project word cloud

Explore the words cloud of the BiomStrip project. It provides you a very rough idea of what is the project "BiomStrip" about.

capacity    form    resource    onset    intensity    explosive    survival    strategies    subsequently    tech    building    difficult    pathophysiological    partnership    stage    overheads    biomarker    covered    time    options    sensitivity    feasibility    histological    sums    spread    gut    markets    fastest    detect    super    therapeutical    business    healthcare    compliance    platform    trl6    diseases    plan    market    sensitive    scalability    selectively    diagnostics    device    model    designed    detecting    strategic    causing    multinational    solution    breakthrough    disruptive    fashion    disease    point    minimised    pregnancy    commercialisation    detection    introduces    highest    biomstrip    companies    gradually    engineer    dysbiosis    offers    vital    therapy    diagnosed    once    alleviating    handled    grown    granting    preventive    ultimately    death    effort    rate    license    spent    suffers    effectiveness    empowering    drastically    deaths    patients    drops    carry    breast    validation    counter    types    burdens    accurate    successfully    invasive    globally    flora    keeping    indicator    workplan    bought    tests    cancer    microbial    transform    risk    sme    screening    entry    costly    pioneering    diagnostic    ipr    vastly   

Project "BiomStrip" data sheet

The following table provides information about the project.

Coordinator
LOGODERM OKTATO ES SZOLGALTATO KORLATOLT FELELOSSEGU TARSASAG 

Organization address
address: GARDONYI GEZA UTCA 39
city: DEBRECEN
postcode: 4032
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Hungary [HU]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-07-01   to  2019-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    LOGODERM OKTATO ES SZOLGALTATO KORLATOLT FELELOSSEGU TARSASAG HU (DEBRECEN) coordinator 50˙000.00

Map

 Project objective

Cancer is the second leading cause of death globally, causing 1 in 6 deaths. If cancer is diagnosed at early stage, it is highly likely to be treated successfully. Once it has grown and spread, therapy is vastly more difficult and costly, and survival rate drops rapidly. Screening is a vital healthcare element for early detection but suffers from burdens of cost, capacity, compliance, and detection sensitivity problems. BiomStrip introduces a pioneering screening solution that can carry out cancer screening in the fashion of the common pregnancy tests. Building on our recent breakthrough results in biomarker validation granting TRL6 stage, we have designed a diagnostic device that is low-cost, non-invasive, accurate, can be handled by consumer, and bought over-the counter. The diagnostic method is based on detecting dysbiosis of gut microbial flora, a highly sensitive indicator of pathophysiological processes able to selectively show disease onset at super-early stage, even before histological changes are observable. The method is ultimately able to detect most cancer types and even other diseases, making it a future platform technology. For highest scalability, fastest time-to-market, explosive growth, low resource-intensity, and minimised risk and overheads, we will license production and commercialisation to established multinational companies, keeping our focus as high-tech SME. Breast cancer will be our market entry point and other diseases will be covered subsequently form own resources. To engineer this Workplan, a feasibility study will assess entry use cases and their markets, analyse business model and partnership options, and evaluate IPR strategies in a Strategic Business Plan. The disruptive approach offers to transform cancer screening from top-down to bottom-up: empowering patients, gradually alleviating healthcare systems large effort and sums spent on preventive cancer diagnostics, and drastically improving therapeutical effectiveness.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BIOMSTRIP" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BIOMSTRIP" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

MCBD (2019)

MCBD (MULTI-CORE BIOPSY DEVICE) INNOVATIVE BIOPSY TECHNOLOGY FOR THE NEW ERA OF TARGETED MEDICINE

Read More  

Plasmanorg (2019)

Environmental-friendly organic chemical synthesis in plasma reactor

Read More  

In-Heal (2019)

Standardised administration device for raw medical herbs

Read More